Letters
Views

Arq. Bras. Oftalmol. 2022; 85 (4): 10.5935/0004-2749.20220039

Total: 2824

Ocular surface toxicity of depatuxizumab mafoditin (ABT-414): case reports

Carlos Rocha-de-Lossada; Carmen Alba Linero; Álvaro Santos Ortega1; Marina Rodríguez Calvo-de-Mora1; Rahul Rachwani1; Davide Borroni2,3; Emilio Alba4; Manuel Benavides Orgaz4; Vito Romano2

DOI: 10.5935/0004-2749.20220039

1. Ophthalmology Department, Hospital Regional Universitario de Málaga, Málaga, Spain
2. Royal Liverpool University Hospital, Liverpool, United Kingdom
3. Department of Doctoral Studies, Riga Stradins University, Latvia
4. Unidad de gestión clínica, Oncología Médica Hospital Regional y Universitario de Málaga. Instituto de Investigación de Biotecnología de Málaga, Málaga, Spain

Corresponding author

Carmen Alba-Linero
E-mail: [email protected]

Funding: This study received no specific financial support

Disclosure of potential conflicts of interest: None of the authors have any potential conflicts of interest to disclose

Informed consent was obtained from all patients included in this study


Read in Portuguese Print PDF English
Open Access
Share

How to cite this article:

Rocha-de-Lossada C, Linero CA, Ortega ÁS, Calvo-de-Mora MR, Rachwani R, Borroni2 D, et al. Toxicidade do depatuxizumabe mafodotina (ABT-414) na superfície ocular: relatos de casos. Arq. Bras. Oftalmol. 2022;85(4):. 10.5935/0004-2749.20220039
Export citation